本文選題：文拉法辛 + 艾司西酞普蘭��； 參考：《華中科技大學(xué)》2013年碩士論文

【摘要】：目的：比較文拉法辛與艾司西酞普蘭治療軀體形式障礙的臨床療效及安全性。 方法：根據(jù)治療方法的不同，將符合美國(guó)精神疾病診斷與統(tǒng)計(jì)手冊(cè)第四版（DSM-IV）軀體形式障礙診斷標(biāo)準(zhǔn)的100例門(mén)診患者隨機(jī)分為文拉法辛組（n=50）和艾司西酞普蘭組（n=50），文拉法辛組服用文拉法辛，第1周口服75mg/d，以后加量為150mg/d；艾司西酞普蘭組服用艾司西酞普蘭，第1周口服10mg/d，以后加量為15mg/d，觀察8周。于治療后的第2、4、8周末進(jìn)行治療效果及副反應(yīng)的評(píng)定，采用漢密爾頓抑郁量表（HAMD），漢密爾頓焦慮量表（HAMA）和不良反應(yīng)癥狀量表（TESS）來(lái)評(píng)定。 結(jié)果：文拉法辛與艾司西酞普蘭治療軀體形式障礙均有療效，兩組在治療前后HAMD及HAMA評(píng)分顯著下降，差異有統(tǒng)計(jì)學(xué)意義（P0.01）；在第2周末，艾司西酞普蘭組的HAMD減分率輕微高于文拉法辛組，差異有統(tǒng)計(jì)學(xué)意義（P0.05）；但是在第4周及第8周末文拉法辛組的HAMD減分率明顯高于艾司西酞普蘭組，差異有統(tǒng)計(jì)學(xué)意義（P 0.01）；另外，文拉法辛組的不良反應(yīng)發(fā)生率為35.42%，艾司西酞普蘭組的不良反應(yīng)發(fā)生率為12%，差異有統(tǒng)計(jì)學(xué)意義（P0.05）。 結(jié)論：文拉法辛治療軀體形式障礙的療效優(yōu)于艾司西酞普蘭，，但是艾司西酞普蘭起效較文拉法辛快，而且藥物的不良反應(yīng)輕，對(duì)患者來(lái)說(shuō)有很好的依從性。
[Abstract]:Objective : To compare the clinical efficacy and safety of Wenlamethod and escitalopram in the treatment of somatoform disorders .

Methods : According to the different methods of treatment , 100 outpatients who met the criteria for the diagnosis and diagnosis of somatic disorders of mental disorders in the United States were randomly divided into Wenlamethod Xin group ( n = 50 ) and escitalopram group ( n = 50 ) .
escitalopram was administered orally for 10 mg / day in the first week and 15 mg / d for 8 weeks . The treatment effect and side effects were assessed at the 2nd , 4th and 8th weekend after treatment .

Results : The curative effect of Wenlamethod and escitalopram in the treatment of somatoform disorder were significant , and the scores of HAMA were significantly decreased in both groups before and after treatment ( P0.01 ) .
At the end of the second week , there was a slight difference between the scores of the escitalopram group ( P0.05 ) .
But in the 4th week and the 8th week , the rate of reduction was significantly higher than that of escitalopram group ( P 0.01 ) .
In addition , the incidence of adverse reactions was 35.42 % , and the incidence of adverse reactions was 12 % in escitalopram group ( P0.05 ) .

Conclusion : The therapeutic effect of Venacine in the treatment of somatoform disorder is better than that of escitalopram , but the efficacy of escitalopram is faster than that of escitalopram , and the adverse reaction of the drug is mild , which is very good for patients .

【學(xué)位授予單位】：華中科技大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2013
【分類號(hào)】：R749.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 周為,何慶華;軀體化障礙患者述情障礙分析[J];臨床精神醫(yī)學(xué)雜志;2005年04期

2 楊占宇;呂新華;劉建林;張文寶;;文拉法辛治療軀體形式障礙對(duì)照研究[J];臨床心身疾病雜志;2006年04期

3 趙蘭民;;軀體化障礙研究進(jìn)展[J];實(shí)用醫(yī)藥雜志;2007年03期

4 孫潤(rùn)珠;薛芬;張華;孫雯雯;彭正午;;艾司西酞普蘭與文拉法辛治療軀體形式障礙療效觀察[J];精神醫(yī)學(xué)雜志;2012年02期

5 陳月江;;艾司西酞普蘭治療軀體形式障礙的臨床療效觀察[J];四川精神衛(wèi)生;2010年03期

6 王東林;軀體形障礙[J];醫(yī)學(xué)綜述;1997年10期

7 施慎遜;王志陽(yáng);;軀體化癥狀和軀體形式障礙[J];中華全科醫(yī)師雜志;2007年07期

本文編號(hào)：1823789